Nuclear medicine combines structural and functional imaging, thus detecting lesions earlier than traditional methodologies. CD147 is a transmembrane glycoprotein that is expressed at very low levels in normal tissues, but significantly overexpressed in tumoral tissues, and is tied to clinical outcome and immune infiltration in cancer.
Understanding the mechanisms that drive the transition from an inflammatory to a proliferative phase during wound healing can aid in developing novel strategies for enhanced tissue repair. Keratinocytes, by undergoing reprogrammed gene expression, play crucial roles in both the inflammatory and proliferative phases of wound healing.
Researchers from Vrise Therapeutics Inc. and Vegen Therapeutics Pvt Ltd. presented preclinical data for VRTX-531, an allosteric inhibitor of ubiquitin carboxyl-terminal hydrolase 1 (USP1), being developed for the treatment of cancer.
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic autoimmune disease characterized by the inflammation of blood vessels, and it has been demonstrated that myeloperoxidase (MPO) is one of the major disease drivers of AAV, as it is a neutrophil surface protein that binds to ANCA.
Hifibio Therapeutics Inc. has gained IND clearance from the FDA for HFB-200604, a potentially best-in-class BTLA agonist monoclonal antibody for inflammatory and immunology diseases.
Damona Pharmaceuticals Inc. has obtained IND clearance from the FDA for DPX-101 for the treatment of cognitive deficits in brain disorders, including major depressive disorder.
Pancreatic ductal adenocarcinoma (PDAC) has a low 5-year survival rate of <12%. Even though KRAS is mutated in about 88% of PDACs, the KRAS G12C mutation is rare, limiting the use of KRAS G12C inhibitors. Hence, there is a need for pan-RAS inhibitors to cover the broad RAS mutation spectrum in PDAC.
Korro Bio Inc. has announced a submission to the Australian Bellberry Human Research Ethics Committee (HREC) for a phase I/II study of KRRO-110 for α-1 antitrypsin deficiency (AATD).